- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Hubert Chen, MD
- Telefonnummer: 8587044660
- E-post: clinicaltrials@vikingtherapeutics.com
Studieorter
-
-
Arizona
-
Tucson, Arizona, Förenta staterna, 85741
- Rekrytering
- Viking Clinical Site #2020
-
Kontakt:
- Telefonnummer: 520-333-4515
-
-
California
-
Lake Forest, California, Förenta staterna, 92630
- Rekrytering
- Viking Clinical Site #2015
-
Kontakt:
- Telefonnummer: 714-550-9990
-
-
Florida
-
Ocoee, Florida, Förenta staterna, 34761
- Rekrytering
- Viking Clinical Site #2059
-
Kontakt:
- Telefonnummer: 407-654-2724
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Rekrytering
- Viking Clinical Site #2013
-
Kontakt:
- Telefonnummer: 404-920-6201
-
-
Indiana
-
Evansville, Indiana, Förenta staterna, 47714
- Rekrytering
- Viking Clinical Site #2001
-
Kontakt:
- Telefonnummer: 812-477-2760
-
Indianapolis, Indiana, Förenta staterna, 46202
- Rekrytering
- Viking Clinical Site #2046
-
Kontakt:
- Telefonnummer: 504-336-2667
-
Valparaiso, Indiana, Förenta staterna, 46383
- Rekrytering
- Viking Clinical Site #2009
-
Kontakt:
- Telefonnummer: 219-464-8302
-
-
Minnesota
-
Richfield, Minnesota, Förenta staterna, 55423
- Rekrytering
- Viking Clinical Site #2004
-
Kontakt:
- Telefonnummer: 952-922-7000
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39206
- Rekrytering
- Viking Clinical Site #2029
-
Kontakt:
- Telefonnummer: 770-330-4157
-
-
Missouri
-
Springfield, Missouri, Förenta staterna, 65807
- Rekrytering
- Viking Clinical Site #2028
-
Kontakt:
- Telefonnummer: 504-338-0917
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87107
- Rekrytering
- Viking Clinical Site #2052
-
Kontakt:
- Telefonnummer: 505-243-1627
-
-
New York
-
Binghamton, New York, Förenta staterna, 13905
- Rekrytering
- Viking Clinical Site #2039
-
Kontakt:
- Telefonnummer: 607-800-5777
-
-
Oregon
-
Medford, Oregon, Förenta staterna, 97504
- Rekrytering
- Viking Clinical Site #2023
-
Kontakt:
- Telefonnummer: 541-858-1018
-
-
Rhode Island
-
East Greenwich, Rhode Island, Förenta staterna, 02818
- Rekrytering
- Viking Clinical Site #2002
-
Kontakt:
- Telefonnummer: 401-739-9350
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29407
- Rekrytering
- Viking Clinical Site #2044
-
Kontakt:
- Telefonnummer: 843-432-2477
-
-
Tennessee
-
Hendersonville, Tennessee, Förenta staterna, 37075
- Rekrytering
- Viking Clinical Site #2030
-
Kontakt:
- Telefonnummer: 504-339-0917
-
-
Texas
-
Abilene, Texas, Förenta staterna, 79606
- Rekrytering
- Viking Clinical Site #2031
-
Kontakt:
- Telefonnummer: 325-400-1150
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Rekrytering
- Viking Clinical Site #2011
-
Kontakt:
- Telefonnummer: 206-536-3030
-
Spokane, Washington, Förenta staterna, 99218
- Rekrytering
- Viking Clinical Site #2042
-
Kontakt:
- Telefonnummer: 509-505-6227
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥18 years of age at the time of signing the informed consent.
- Body mass index (BMI) ≥ 27 kg/m2
- Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.
Exclusion Criteria:
-
History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
-
Self-reported body weight change of 5% or more within 3 months of screening
-
Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
-
Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
-
Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
-
Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening
• Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG < 54 mg/dL.
-
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
-
Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
-
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
-
History of acute or chronic pancreatitis
-
Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo Assignment
Placebo comparator orally once daily |
Placebo comparator administered orally once daily |
|
Experimentell: Active Assignment (Dose 1)
VK2735 Dose level 1 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Experimentell: Active Assignment (Dose 2)
VK2735 Dose level 2 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
|
Experimentell: Active Assignment (Dose 3)
VK2735 Dose level 3 orally once daily |
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily
Tidsram: 68 weeks
|
To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 |
68 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- VK2735-305
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .